Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

摘要: The traditional approach to the treatment of patients with advanced-stage non-small-cell lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been sequential administration therapies (sequential approach), in which first receive first-generation tyrosine-kinase inhibitors (TKIs), are eventually replaced by next-generation TKIs and/or chemotherapy upon disease progression, a decision optionally guided tumour molecular profiling. In past few years, this strategy challenged by clinical evidence showing improved progression-free survival, intracranial control and generally favourable toxicity profile when used first-line setting. Review, we describe existing preclinical clinical supporting both strategies — ‘historical’ use as frontline discuss suitability for EGFR-driven ALK-driven NSCLC. management greatly evolved owing development (TKIs) targeted against driver disease. authors Review on upfront.